Xenon Pharmaceuticals (XENE) Revenue & Revenue Breakdown
Xenon Pharmaceuticals Revenue Highlights
00
Main Segment (Y)
License and Service
Xenon Pharmaceuticals Revenue by Period
Xenon Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | -100.00% |
| 2022-12-31 | $9.43M | -48.83% |
| 2021-12-31 | $18.44M | -42.68% |
| 2020-12-31 | $32.17M | 371.02% |
| 2019-12-31 | $6.83M | 100.00% |
| 2018-12-31 | - | -100.00% |
| 2017-12-31 | $311.00K | -82.75% |
| 2016-12-31 | $1.80M | -88.43% |
| 2015-12-31 | $15.58M | -45.09% |
| 2014-12-31 | $28.37M | 3.71% |
| 2013-12-31 | $27.36M | 91.19% |
| 2012-12-31 | $14.31M | 106.82% |
| 2011-12-31 | $6.92M | - |
Xenon Pharmaceuticals generated - in revenue during NA 2023, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Xenon Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $5.38M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | -100.00% |
| 2022-12-31 | $8.77K | -93.36% |
| 2022-09-30 | $132.00K | -75.37% |
| 2022-06-30 | $536.00K | -93.89% |
| 2022-03-31 | $8.77M | 134.57% |
| 2021-12-31 | $3.74M | -54.00% |
| 2021-09-30 | $8.12M | 266.28% |
| 2021-06-30 | $2.22M | -49.11% |
| 2021-03-31 | $4.36M | -15.38% |
| 2020-12-31 | $5.15M | -21.42% |
| 2020-09-30 | $6.55M | -51.03% |
| 2020-06-30 | $13.38M | 89.09% |
| 2020-03-31 | $7.08M | 112.62% |
| 2019-12-31 | $3.33M | -4.89% |
| 2019-09-30 | $3.50M | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $6.00M | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $16.00K | -93.94% |
| 2017-09-30 | $264.00K | 1660.00% |
| 2017-06-30 | $15.00K | -6.25% |
| 2017-03-31 | $16.00K | -95.74% |
| 2016-12-31 | $376.00K | -8.96% |
| 2016-09-30 | $413.00K | - |
| 2016-06-30 | $413.00K | -31.28% |
| 2016-03-31 | $601.00K | -81.38% |
| 2015-12-31 | $3.23M | -24.85% |
| 2015-09-30 | $4.29M | 6.13% |
| 2015-06-30 | $4.05M | 0.90% |
| 2015-03-31 | $4.01M | -17.79% |
| 2014-12-31 | $4.88M | -63.03% |
| 2014-09-30 | $13.19M | 149.02% |
| 2014-06-30 | $5.30M | 5.94% |
| 2014-03-31 | $5.00M | -10.42% |
| 2013-12-31 | $5.58M | -48.25% |
| 2013-09-30 | $10.79M | - |
Xenon Pharmaceuticals generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Xenon Pharmaceuticals Revenue Breakdown
Xenon Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|
| License and Service | $9.43M | - | - |
| License And Service | - | $18.44M | $32.17M |
Latest
Xenon Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: License and Service (100.00%).
Quarterly Revenue by Product
| Product/Service | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 |
|---|---|---|---|---|---|---|---|
| License And Service | $132.00K | $536.00K | $8.77M | $2.85M | $2.22M | $4.36M | $5.15M |
Latest
Xenon Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License And Service (100.00%).
Xenon Pharmaceuticals Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Dec 20 |
|---|---|---|---|---|---|---|---|
| License And Service | $132.00K | $536.00K | $8.77M | $2.85M | $2.22M | $4.36M | $5.15M |
Latest
Xenon Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Sep 22: License And Service (100.00%).
Xenon Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| UTHR | United Therapeutics | $2.33B | $748.90M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| ACLX | Arcellx | $110.32M | $26.03M |
| MRUS | Merus | $43.95M | $11.77M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| ANAB | AnaptysBio | $17.16M | $30.02M |
| MGTX | MeiraGTx | $14.02M | $10.91M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| KRON | Kronos Bio | $6.29M | $2.37M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| INBX | Inhibrx Biosciences | $1.80M | - |
| FIXX | Q32 Bio | $1.16M | - |
| KRTX | Karuna Therapeutics | $654.00K | - |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| KROS | Keros Therapeutics | $151.00K | $37.00K |
| LYEL | Lyell Immunopharma | $130.00K | $34.00K |
| XENE | Xenon Pharmaceuticals | - | - |
| PCVX | Vaxcyte | - | - |
| NUVL | Nuvalent | - | - |
| DICE | DICE Therapeutics | - | - |
| DYN | Dyne Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| VTYX | Ventyx Biosciences | - | - |
| EWTX | Edgewise Therapeutics | - | - |